Balchem CORP

Balchem Corporation announced record net sales, net earnings, and adjusted EBITDA for the second quarter of 2026, driven by strong performance across all three reporting segments.

Balchem Corporation announced an amendment to its credit agreement, increasing the revolving commitment amount and extending the maturity date.

Balchem Corporation announced record first quarter net sales, adjusted EBITDA, and net earnings, with growth across all three business segments.

Balchem Corporation announced record net sales, adjusted EBITDA, and free cash flow for both the fourth quarter and full year ended December 31, 2025, driven by growth across all segments.

Balchem Corporation announced the election of Erin L. Gilson as its new Vice President and Chief Accounting Officer, effective April 1, 2026, succeeding William A. Backus upon his retirement.

Balchem Corporation announced a 10.3% increase in its annual dividend to $0.96 per share and a new stock repurchase program for up to 4 million shares.

Balchem Corporation reported a 16.6% increase in net earnings for the second quarter of 2026, driven by robust sales growth across its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments.

Balchem Corporation reported strong Q1 2026 results with net sales of $270.7 million, an 8.1% increase year-over-year, driven by growth in all business segments.

Balchem Corporation reports robust financial performance for Q3 2025, with significant increases in net sales and earnings across all segments, driven by favorable market conditions and strategic initiatives.

Balchem Corporation announced significant increases in net sales and net earnings for the second quarter and first half of 2025, fueled by robust performance across all its business segments.

Balchem Corporation's Q1 2025 net earnings increased by 27.8% year-over-year, driven by sales growth across all segments and improved gross margins.

Balchem Corporation's third quarter 2024 results show a 16.4% increase in net earnings compared to the same period last year, driven by growth in the Human Nutrition & Health segment.

Balchem Corporation's 2024 10-K filing reveals a 3.4% increase in net sales and an 18.4% increase in net earnings compared to the previous year, driven by growth in the Human Nutrition and Health segment.

Balchem Corporation's Form 10-K filing details the company's securities registered under Section 12 of the Securities Exchange Act of 1934, primarily its common stock.

A Balchem Corporation executive reported the acquisition of restricted stock and performance units, alongside shares withheld for tax obligations, and new stock option grants.

Balchem Corporation's SVP Chief Supply Chain Officer, Martin Luther Reid, reported the acquisition of restricted stock and performance units, alongside new stock options, and shares withheld for tax obligations.

Balchem Corporation's Chairman, President & CEO, Theodore L. Harris, reported significant equity awards, including restricted stock, performance units, and stock options, alongside shares withheld for tax obligations.

Balchem Corporation's SVP and Chief R&D Officer, George Graham, reported the acquisition of 700 restricted stock units and 2,600 stock options.

Balchem Corporation's VP & Chief Accounting Officer, William A. Backus, reported the acquisition of restricted stock and performance units, along with stock option grants and shares withheld for tax obligations.

Balchem Corporation's SVP Frederic Boned reported recent equity transactions, including restricted stock grants, performance unit vesting, and stock option awards, alongside tax-related share dispositions.

Balchem Corporation has issued its 2026 Proxy Statement, inviting shareholders to its virtual Annual Meeting on June 18, 2026, to vote on director elections, auditor ratification, and executive compensation.

Balchem Corporation has filed a definitive proxy statement with the SEC.

Balchem Corporation's 2025 Annual Meeting of Shareholders will be held virtually on June 18, 2025, with shareholders encouraged to vote on key proposals and review the company's strong 2024 financial and sustainability achievements.

Balchem Corporation has filed a definitive proxy statement with the SEC.

Balchem Corporation's 2024 Annual Meeting of Shareholders will be held virtually on June 20, 2024, covering director elections, auditor ratification, and executive compensation.

Vanguard Capital Management has reported beneficial ownership of 5.24% of Balchem Corp's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.93% in Balchem Corp's common stock as of March 31, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 14.4% of Balchem Corp's common stock as of June 30, 2025.

APG Asset Management US Inc., APG Asset Management, N.V., APG Group, and Stichting Pensioenfonds ABP have jointly filed an amendment to their Schedule 13G, disclosing a shared beneficial ownership of 3.7% in Balchem Corp's common stock as of March 31, 2025.

APG Asset Management US Inc., APG Asset Management N.V., APG Group, and Stichting Pensioenfonds ABP have jointly reported a 6.1% beneficial ownership stake in Balchem Corp's common stock as of December 31, 2024.